299 related articles for article (PubMed ID: 36136544)
1. Antibodies as Snakebite Antivenoms: Past and Future.
Dias da Silva W; De Andrade SA; Megale ÂAA; De Souza DA; Sant'Anna OA; Magnoli FC; Guidolin FR; Godoi KS; Saladini LY; Spencer PJ; Portaro FCV
Toxins (Basel); 2022 Sep; 14(9):. PubMed ID: 36136544
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa.
Harrison RA; Oluoch GO; Ainsworth S; Alsolaiss J; Bolton F; Arias AS; Gutiérrez JM; Rowley P; Kalya S; Ozwara H; Casewell NR
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005969. PubMed ID: 29045429
[TBL] [Abstract][Full Text] [Related]
3. Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa.
Williams DJ; Gutiérrez JM; Calvete JJ; Wüster W; Ratanabanangkoon K; Paiva O; Brown NI; Casewell NR; Harrison RA; Rowley PD; O'Shea M; Jensen SD; Winkel KD; Warrell DA
J Proteomics; 2011 Aug; 74(9):1735-67. PubMed ID: 21640209
[TBL] [Abstract][Full Text] [Related]
4. Commercial Antivenoms Exert Broad Paraspecific Immunological Binding and In Vitro Inhibition of Medically Important
Alsolaiss J; Alomran N; Hawkins L; Casewell NR
Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668821
[TBL] [Abstract][Full Text] [Related]
5. Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
Alomran N; Alsolaiss J; Albulescu LO; Crittenden E; Harrison RA; Ainsworth S; Casewell NR
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009659. PubMed ID: 34407084
[TBL] [Abstract][Full Text] [Related]
6. Snake venomics and antivenomics: Proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming.
Gutiérrez JM; Lomonte B; León G; Alape-Girón A; Flores-Díaz M; Sanz L; Angulo Y; Calvete JJ
J Proteomics; 2009 Mar; 72(2):165-82. PubMed ID: 19344652
[TBL] [Abstract][Full Text] [Related]
7. Current research into snake antivenoms, their mechanisms of action and applications.
Silva A; Isbister GK
Biochem Soc Trans; 2020 Apr; 48(2):537-546. PubMed ID: 32196542
[TBL] [Abstract][Full Text] [Related]
8. Computer-Aided Analysis of West Sub-Saharan Africa Snakes Venom towards the Design of Epitope-Based Poly-Specific Antivenoms.
Ros-Lucas A; Bigey P; Chippaux JP; Gascón J; Alonso-Padilla J
Toxins (Basel); 2022 Jun; 14(6):. PubMed ID: 35737079
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the intrageneric neutralization scope of monospecific, bispecific/monogeneric and polyspecific/monogeneric antisera raised in horses immunized with sub-Saharan African snake venoms.
Sánchez A; Durán G; Segura Á; Herrera M; Vargas M; Villalta M; Arguedas M; Moscoso E; Umaña D; Gómez A; Gutiérrez JM; León G
PLoS Negl Trop Dis; 2024 May; 18(5):e0012187. PubMed ID: 38809847
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms.
Alomran N; Blundell P; Alsolaiss J; Crittenden E; Ainsworth S; Dawson CA; Edge RJ; Hall SR; Harrison RA; Wilkinson MC; Menzies SK; Casewell NR
Toxins (Basel); 2022 Jun; 14(7):. PubMed ID: 35878181
[TBL] [Abstract][Full Text] [Related]
11. Antivenomics and in vivo preclinical efficacy of six Latin American antivenoms towards south-western Colombian Bothrops asper lineage venoms.
Mora-Obando D; Pla D; Lomonte B; Guerrero-Vargas JA; Ayerbe S; Calvete JJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009073. PubMed ID: 33524033
[TBL] [Abstract][Full Text] [Related]
12. A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.
Ratanabanangkoon K
Front Immunol; 2021; 12():668328. PubMed ID: 33968072
[TBL] [Abstract][Full Text] [Related]
13. Polyvalent Snake Antivenoms: Production Strategy and Their Therapeutic Benefits.
Ratanabanangkoon K
Toxins (Basel); 2023 Aug; 15(9):. PubMed ID: 37755943
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa.
Khochare S; Jaglan A; Rashmi U; Dam P; Sunagar K
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673799
[TBL] [Abstract][Full Text] [Related]
15. Antivenoms for snakebite envenomings.
Gutiérrez JM; León G; Lomonte B; Angulo Y
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):369-80. PubMed ID: 21745181
[TBL] [Abstract][Full Text] [Related]
16. Recombinant snake antivenoms get closer to the clinic.
Laustsen AH
Trends Immunol; 2024 Apr; 45(4):225-227. PubMed ID: 38538486
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.
Gutiérrez JM; León G; Lomonte B
Clin Pharmacokinet; 2003; 42(8):721-41. PubMed ID: 12846594
[TBL] [Abstract][Full Text] [Related]
18. Omics meets biology: application to the design and preclinical assessment of antivenoms.
Calvete JJ; Sanz L; Pla D; Lomonte B; Gutiérrez JM
Toxins (Basel); 2014 Dec; 6(12):3388-405. PubMed ID: 25517863
[TBL] [Abstract][Full Text] [Related]
19. Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.
Laustsen AH; Dorrestijn N
Toxins (Basel); 2018 Jul; 10(8):. PubMed ID: 30065185
[TBL] [Abstract][Full Text] [Related]
20. Cross neutralization of coral snake venoms by commercial Australian snake antivenoms.
Ramos HR; Vassão RC; de Roodt AR; Santos E Silva EC; Mirtschin P; Ho PL; Spencer PJ
Clin Toxicol (Phila); 2017 Jan; 55(1):33-39. PubMed ID: 27595162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
